Hypothesis

In aged plasma cells, immunoglobulin aggregation represents an active proteostasis containment strategy rather than passive failure. Misfolded or damaged immunoglobulins get sequestered into SDS-resistant crystalline aggregates, preserving secretory function at the cost of antibody quality. This trade-off explains the well-documented decline in antibody affinity and the rise in autoreactivity observed in aging humoral immunity.

Mechanistic Framework

Plasma cells face a unique proteostatic challenge: they must secrete enormous quantities of immunoglobulins for decades while maintaining proteome integrity. As proteasome and ERAD efficiency decline with age and oxidative damage accumulates, misfolded immunoglobulin species inevitably build up. Instead of overwhelming degradation capacity or triggering the unfolded protein response—which would lead to apoptosis—aged plasma cells appear to adopt what we call a "crystalline containment" strategy.

This model builds on the idea that protein aggregation can represent thermodynamically stable outcomes when proteostatic options are exhausted. The cell converts disordered, potentially toxic misfolded immunoglobulins into inert β-sheet-rich crystalline aggregates through a process that:

1. Neutralizes proteotoxic species by sequestering reactive misfolded intermediates into stable, non-functional crystals
2. Preserves secretory capacity by preventing ER stress accumulation that would otherwise shut down antibody production
3. Maintains plasma cell survival by avoiding apoptosis triggered by proteostatic collapse

The Quality Trade-Off

This strategy, however, carries an immunological cost. Active containment diverts cellular resources—chaperones, degradation machinery, metabolic energy—toward aggregate maintenance rather than fidelity enforcement. Additionally, the sequestration process may preferentially retain structurally compromised but secretion-competent immunoglobulin variants. This would explain why aged plasma cells produce lower-affinity antibodies with increased self-reactivity [https://pmc.ncbi.nlm.nih.gov/articles/PMC4687518/]. The system prioritizes "good enough" secretion over optimal affinity.

This model addresses an apparent paradox in immunosenescence: why would the immune system produce inferior antibodies if the B cell machinery is largely intact? The answer may be that plasma cells are making a strategic choice—sacrificing antibody quality to maintain the critical function of sustained immunoglobulin secretion, which is essential for preserving immunological memory even if that memory is imperfect.

Testable Predictions

1. Aged plasma cells will show colocalization of misfolded immunoglobulin intermediates with SDS-resistant aggregates, suggesting active sequestration rather than random accumulation
2. Inhibiting aggregate formation (e.g., with small molecule β-sheet breakers or proteostasis enhancers) in aged plasma cells should temporarily improve antibody affinity but may trigger ER stress and reduce secretory capacity
3. Transcriptomic analysis will reveal upregulated chaperones and aggregation-associated genes (e.g., Hsp70 family, small heat shock proteins) specifically in aged plasma cells, not merely global senescence markers
4. Cross-sectional comparison of plasma cells from young versus elderly individuals will show inverse correlation between intracellular aggregate load and secreted antibody affinity—high aggregate load predicts lower-affinity output

Falsifiability

This hypothesis is falsifiable if: (a) aged plasma cells show no immunoglobulin-containing aggregates despite impaired proteostasis, indicating dissolution rather than sequestration; (b) inhibiting aggregation improves antibody quality without compromising plasma cell survival or secretion rates; or (c) transcriptomic data reveals no upregulation of aggregation-handling pathways in aged plasma cells, suggesting passive accumulation rather than regulated containment.

The critical gap this addresses is the lack of studies examining proteostasis mechanisms in cells that secrete the most abundant proteins in the body—immunoglobulins—across decades of human life. If validated, this framework would shift therapeutic approaches from "dissolving aggregates" to "optimizing the containment-fidelity trade-off" in age-related immune decline.